Policy & Regulation
Matica Biotechnology signs joint research agreement with Sartorius
19 October 2021 -

Matica Biotechnology Inc, a US-based contract development and manufacturing organisation, announced on Monday that it has signed a joint research agreement with Sartorius, a US-based international partner to the biopharmaceutical industry.

According to the contract, both firms will work on various studies together to streamline and optimise PAT technologies, automation software, and single-use platforms provided by Sartorius for large scale vector production.

Michael Stewart, chief technology officer at Matica Bio, said, 'The generation of in-line real-time process data is one of the most significant obstacles to achieving consistent, high-producing viral vector titers during development that can be translatable to large scale production. In many respects, what is going on inside a bioreactor or within downstream operations is still a black box to us. Matica Bio's development, manufacturing and quality teams have decades of viral vector production experience. Applying our expertise together with Sartorius' industry-leading single-use and PAT technologies will allow us to provide more robust, consistent results for our clients, guiding informed decision-making throughout the manufacturing process and accelerating the overall development timeline to the clinic and market.'

Login
Username:

Password: